US Stock Futures Edge Higher Ahead Of Empire State Manufacturing Index
US stock futures traded higher in early pre-market trade. The Empire State manufacturing index for November will be released at 8:30 a.m. ET. Futures for the Dow Jones Industrial Average surged 27.5 points to 17,233.5, while the Standard & Poor's 500 index futures rose 4.50 points to 2,023.00. Futures for the Nasdaq 100 index gained 8 points to 4,510.00.
A Peek Into Global Markets
European markets were higher today, with the Spanish Ibex Index rising 0.02 percent, STOXX Europe 600 Index surging 0.37 percent and German DAX 30 index gaining 0.48 percent. French CAC 40 Index climbed 0.15 percent and London's FTSE 100 Index rose 0.40 percent.
In Asian markets, Japan's Nikkei Stock fell 1.04 percent, Hong Kong's Hang Seng Index dipped 1.72 percent, China's Shanghai Composite Index rose 0.73 percent and India's BSE Sensex climbed 0.58 percent.
Analysts at Goldman Sachs downgraded Progressive Corp (NYSE: PGR) from Neutral to Sell and lowered the price target to $28.00.
Progressive shares closed at $5.84 on Thursday.
- Cna Financial Corp (NYSE: CNA) today announced the appointment of Dino E. Robusto as its chairman and chief executive officer, effective on or about December 1, 2016. To read the full news, click here.
- Nexvet Biopharma plc (NASDAQ: NVET) today announced positive results from its pivotal safety and efficacy study of NV-01, the Company's anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy in development for the control of pain associated with osteoarthritis in dogs. To read the full news, click here.
- International Business Machines Corp. (NYSE: IBM), and Xilinx, Inc. (NASDAQ: XLNX), today announced a multi-year strategic collaboration to enable higher performance and energy-efficient data center applications through Xilinx FPGA-enabled workload acceleration on IBM POWER-based systems. To read the full news, click here.
- Arrowhead Research Corp (NASDAQ: ARWR) presented data at the AASLD Liver Meeting 2015 in an oral presentation and a poster showing that ARC-520, its drug candidate against chronic hepatitis B infection (HBV), leads to robust, sustained anti-viral effects in chimpanzees with chronic HBV. To read the full news, click here.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.